FBC
ABBV icon

Fairfield, Bush & Co’s AbbVie ABBV Stock Holding History

Fairfield, Bush & Co’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.77M Buy
7,031
+276
+4% +$59.4K 0.87% 34
2026
Q1 		$1.47M Sell
6,755
-141
-2% -$31.3K 0.82% 37
2025
Q4 		$1.58M Buy
6,896
+729
+12% +$166K 0.83% 35
2025
Q3 		$1.43M Buy
6,167
+152
+3% +$31K 0.73% 37
2025
Q2 		$1.12M Sell
6,015
-16
-0.3% -$2.97K 0.63% 45
2025
Q1 		$1.26M Sell
6,031
-218
-3% -$42.4K 0.8% 37
2024
Q4 		$1.11M Buy
6,249
+2,739
+78% +$504K 0.65% 44
2024
Q3 		$693K Buy
3,510
+335
+11% +$62.5K 0.41% 63
2024
Q2 		$545K Sell
3,175
-943
-23% -$156K 0.33% 61
2024
Q1 		$750K Sell
4,118
-773
-16% -$133K 0.44% 57
2023
Q4 		$758K Sell
4,891
-388
-7% -$56.6K 0.44% 55
2023
Q3 		$787K Sell
5,279
-198
-4% -$29.1K 0.51% 50
2023
Q2 		$738K Sell
5,477
-222
-4% -$32.6K 0.2% 89
2023
Q1 		$908K Sell
5,699
-923
-14% -$141K 0.32% 71
2022
Q4 		$1.07M Sell
6,622
-48
-0.7% -$7.36K 0.71% 39
2022
Q3 		$895K Buy
6,670
+834
+14% +$120K 0.63% 42
2022
Q2 		$894K Sell
5,836
-2,868
-33% -$438K 0.53% 46
2022
Q1 		$1.41M Sell
8,704
-667
-7% -$96.9K 0.71% 36
2021
Q4 		$1.27M Buy
9,371
+972
+12% +$115K 0.61% 42
2021
Q3 		$906K Buy
8,399
+2,435
+41% +$278K 0.29% 75
2021
Q2 		$671K Buy
5,964
+400
+7% +$45K 0.18% 96
2021
Q1 		$602K Sell
5,564
-501
-8% -$53.6K 0.17% 106
2020
Q4 		$650K Buy
6,065
+2,125
+54% +$204K 0.19% 97
2020
Q3 		$345K Buy
+3,940
New +$371K 0.11% 114
2018
Q2 		– Sell
-1,540
Closed -$146K – 158
2018
Q1 		$146K Buy
+1,540
New +$169K 0.04% 157

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fairfield, Bush & Co's ABBV Position: Q2 2026 in Review

Fairfield, Bush & Co increased its AbbVie (ABBV) stake by 4.1% in Q2 2026, buying an estimated $59.4K and bringing the position to 7,031 shares worth $1.77M. The position accounts for 0.87% of the portfolio, ranked #34.

Fairfield, Bush & Co first reported a position in ABBV in Q1 2018 and has held it in 25 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Fairfield, Bush & Co held 7,031 shares of AbbVie worth $1.77M as of Q2 2026.
  • Fairfield, Bush & Co bought 276 AbbVie shares in Q2 2026, an estimated $59.4K.
  • AbbVie made up 0.87% of Fairfield, Bush & Co's portfolio in Q2 2026, its #34 holding.
  • Fairfield, Bush & Co first reported a position in AbbVie in Q1 2018 and has held it in 25 quarters since.
  • 4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fairfield, Bush & Co's 13F filing for Q2 2026, filed 13 Aug 2026.